Special Section: Autologous Stem Cell Transplantations in Solid Tumours: Incidence and Prevention of Nonhaematological Toxicity of High-dose Chemotherapy

References

• Frei E. Pharmacologio strategies for high dose chemotherapy. High-dose Chemotherapy, J C Armitage, KH Antman. Williams & Witkins, Baltimore 1992; 3–13
   Google Scholar
• Peters W P, Ross M, Vredenburgh J J, et al. High-dose chemotherapy and autologous bone marrow support as consolidation after standard-dose adjuvant therapy for high-risk primary breast cancer. J Clin Oncol 1993; 11: 1132–43
   PubMed Web of Science ®Google Scholar
• Ayash L J, Elias A, Wheeler C, et al. Double dose-intensive chemotherapy with autologous marrow and peripheral-blood progenitor-cell support for metastatic breast cancer: a feasibility study. J Clin Oncol 1994; 12: 37–44
   PubMed Web of Science ®Google Scholar
• van der Wall E, Nooijen W J, Baars J W, et al. High-dose carboplatin, thiotepa and cyclophosphamide (CTC) with peripheral stem cell support in the adjuvant therapy of high-risk breast cancer: a practical approach. Br J Cancer 1995; 71: 857–62
   PubMedGoogle Scholar
• Antman K H, Ayash L, Elias A, et al. A phase II study of high-dose cyclophosphamide, thiotepa and carboplatin with autologous marrow support in women with measurable advanced breast cancer responding to standard-dose therapy. J Clin Oncol 1992; 10: 102–10
   PubMed Web of Science ®Google Scholar
• Patrone F, Ballestrero A, Ferrando F, et al. Four-step high-dose sequential chemotherapy with double hematopoietic progenitor-cell rescue for metastatic breast cancer. J Clin Oncol 1995; 13: 840–6
   PubMedGoogle Scholar
• Fennelly D, Schneider J, Spriggs D, et al. Dose escalation of paclitaxel with high-dose cyclophosphamide, with analysis of progenitor-cell mobilization and hematologic support of advanced oavarian cancer patients receiving rapidly sequenced high-dose carboplatin/cyclophosphamide courses. J Clin Oncol 1995; 13: 1160–6
   PubMedGoogle Scholar
• Leyvraz S, Kettere N, Perey L, et al. Intensification of chemotherapy for the treatment of solid tumours: feasibility of a 3-fold increase in dose intensity with peripheral blood progenitor cells and granulocyte colony-stimulating factor. Br J Cancer 1995; 72: 178–82
   PubMedGoogle Scholar
• van der Wall E, Beijnen J H, Rodenhuis S. High-dose chemotherapy regimens for solid tumours. Cancer Treat Rev 1995; 21: 105–32
   PubMed Web of Science ®Google Scholar
• Fields K K, Elfenbein G J, Lazarus H M, et al. Maximumtolerated doses of ifosfamide, carboplatin, and etoposide given over 6 days followed by autologous stem-cell rescue: toxicity profile. J Clin Oncol 1995; 13: 323–32
   PubMed Web of Science ®Google Scholar
• Pittman K B, To L B, Bayly J L, et al. Non-haematological toxicity limiting the application of sequential high dose chemotherapy in patients with advanced breast cancer. Bone Marrow Transpl 1992; 10: 535–40
   PubMed Web of Science ®Google Scholar
• Rodenhuis S, Baars J W, Schornagel J H, van der Wall E, Holtkamp M, Nooijen W J. Multiple courses of high-dose cyclophosphamide, thiotepa and carboplatin (CTC) with autologous stem cell support. Proc Am Soc Clin Oncol 1995, Abstract 914
   Google Scholar
• Perez E A. Review of the preclinical pharmacology and comparative efficacy of 5-hydroxytryptamine-3 receptor antagonists for chemotherapy-induced emesis. J Clin Oncol 1995; 13: 1036–43
   PubMed Web of Science ®Google Scholar
• Navari R M, Province W S, Perrine G M, Kilgore J R. Comparison of intermittent ondansetron vs. continuous infusion of metoclopramide used with standard combination antiemetics in control of acute nausea induced by cisplatin chemotherapy. Cancer 1993; 72: 583–6
   PubMed Web of Science ®Google Scholar
• Navari R M, Gandara D, Heskett P, et al. Comparative clinical trial of granisetron and ondansetron in the prophylaxis of cisplatin-induced emesis. J Clin Oncol 1995; 133: 1242–8
   Google Scholar
• Jantunen I T, Muhonen T T, Kataja W, Flander M K, Teerenhovi L. 5-HT3 receptor antagonists in the prophylaxis of acute vomiting induced by moderately emetogenic chemotherapy. A randomized study. Eur J Cancer 1993; 29a: 1669–72
   PubMed Web of Science ®Google Scholar
• Hesketh P J, Beck T, Uhlenhopp M, et al. Adjusting the dose of intravenous ondansetron plus dexamethason to the emetogenic potential of the chemotherapy regimen. J Clin Oncol 1995; 13: 2117–22
   PubMed Web of Science ®Google Scholar
• Grunberg S M, Lane M, Lester E P, et al. Randomized double-blind comparison of three dose levels of intravenous ondansetron in the prevention of cisplatin-induced emesis. Cancer Chemother Pharmacol 1993; 32: 268–72
   PubMed Web of Science ®Google Scholar
• Kaizer L, Warr D, Hoskins P, et al. Effect of schedule and maintenance on the antiemetic efficacy of ondansetron combined with dexamethasone in acute and delayed nausea and emesis in patients receiving moderately emetogenic chemotherapy: a phase III trial by the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 1994; 12: 1050–7
   PubMed Web of Science ®Google Scholar
• Hesketh P J, Harvey W H, Harker W G, et al. A randomized, double-blind comparison of intravenous ondansetron alone and in combination with intravenous dexamethasone in the prevention of high-dose cisplatin-induced emesis. J Clin Oncol 1994; 12: 596–600
   PubMed Web of Science ®Google Scholar
• The Italian Group for Antiemetic Research. Dexamethasone, granisetron, or both for the prevention of nausea and vomiting during chemotherapy for cancer. N Engl J Med 1995; 332: 1–5
   PubMed Web of Science ®Google Scholar
• Murgia L, Zamkopff K. Effective control of nausea and vomiting using infusional perphenazine in patients with breast cancer undergoing high dose chemotherapy with cyclophosphamide, thiotepa, carboplatin (CTCb) followed by peripheral blood stem cell transplant. Proc Am Soc Clin Oncol 1995, Abstract 971
   Google Scholar
• Lew M A, Kehoe K, Ritz J, et al. Ciprofloxacin vs. trimethoprim/sulfamethoxazole for prophylaxis of bacterial infections in bone marrow transplant recipients: a randomized, controlled trial. J Clin Oncol 1995; 13: 239–50
   PubMedGoogle Scholar
• Hughes W T, Armstrong D, Bodey G P, et al. Guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever. J Infect Dis 1990; 161: 381–96
   PubMed Web of Science ®Google Scholar
• Freifeld A G, Walsh T, Marshall D, et al. Monotherapy for fever and neutropenia in cancer patients: a randomized comparison of ceftazidime vs. imipenem. J Clin Oncol 1995; 13: 165–76
   PubMed Web of Science ®Google Scholar
• Maschmeyer G, Link H, Hiddemann W, et al. Pulmonary infiltrations in febrile patients with neutropenia. Risk factors and outcome under empirical antimicrobial therapy in a randomized multicenter study. Cancer 1994; 73: 2296–304
   PubMed Web of Science ®Google Scholar
• Levine S J. An approach to the diagnosis of pulmonary infections in immunosuppressed patients. Semin Respir Infect 1992; 7: 81–95
   PubMedGoogle Scholar
• Swerdloff J N, Filler S G, Edwards J E. Severe candidal infections in neutropenic patients. Clin Infect Dis 1993; 17: S457–67
   Google Scholar
• Allen A. The cardiotoxicity of chemotherapeutic drugs. Semin Oncol 1992; 19: 529–42
   PubMed Web of Science ®Google Scholar
• Rubin P, Petros W, Vredenbirgh J, et al. Cyclophosphamide-induced cardiomyopathy following highdose chemotherapy. Proc Am Soc Clin Oncol 1995, Abstract 968
   Google Scholar
• Herman E H, Witiak D T, Hellman K, Waravdekar V S. Biological properties of ICRF-159 and related bis(dioxopiperazine) compounds. Adv Pharmacol Chemother 1982; 19: 249–90
   PubMedGoogle Scholar
• Speyer J L, Green M D, Zeleniuch-Jacquotte A, et al. ICRF-187 permits longer treatment with doxorubicin in women with breast cancer. J Clin Oncol 1992; 10: 117–27
   PubMed Web of Science ®Google Scholar
• van Acker S ABE, Voest E E, Beems R B, et al. Cardioprotective properties of O-(b-hydroxyethyl)-rutosides in doxorubicin-pretreated BALB/c mice. Cancer Res 1993; 53: 4603–7
   PubMed Web of Science ®Google Scholar
• Dorr R T, Lagel K E. Anthracycline cardioprotection by amifostine (WR-2721) and its active metabolite (WR-1065) in vitro. Proc Am Soc Clin Oncol 1994, Abstract 1495
   PubMedGoogle Scholar
• Jones R B, Matthes S, Shpall E J, et al. Acute lung injury following treatment with high-dose cyclophosphamide, cisplatin, and carmustine: pharmacodynamic evaluation of carmustine. J Natl Cancer Inst 1993; 85: 640–7
   PubMed Web of Science ®Google Scholar
• Todd N W, Peters W P, Ost A H, Roggli V L, Piantadosi C A. Pulmonary drug toxicity in patients with primary breast cancer treated with high-dose combination chemotherapy and autologous bone marrow transplantation. Am Rev Respir Dis 1993; 147: 1264–70
   PubMed Web of Science ®Google Scholar
• Anscher M S, Peters W P, Reisenbichler H, Petros W P, Jirtle R L. Transforming growth factor β as a predictor of liver and lung fibrosis after autologous bone marrow transplantation for advanced breast cancer. N Engl J Med 1993; 328: 1592–8
   PubMed Web of Science ®Google Scholar
• Bearman S I, Anderson G L, Mori M, Hinds M S, Shulman H M, McDonald G B. Veno-occlusive disease of the liver: development of a model for predicting fatal outcome after marrow transplantation. J Clin Oncol 1993; 11: 1729–36
   PubMed Web of Science ®Google Scholar
• Bearman S I, Shuart M C, Hinds M S, et al. Recombinant human tissue plasminogen activator for the treatment of established severe veno-occlusive disease of the liver after bone marrow transplantation. Blood 1992; 80: 2458–62
   PubMed Web of Science ®Google Scholar
• Kemp G M. Amifostine selectively protects against acute and cumulative hematologic and renal toxicities of cyclophosphamide and cisplatin in patients with advanced ovarian cancer. Advances on Gynaecological Oncology, J Bonte, T Maggino. CIC Edizioni Intern, Rome 1995; 197–201
   Google Scholar
• Alberts D S, Noel J K. Cisplatin-associated neurotoxicity: can it be prevented?. Anticancer Drugs 1995; 6: 369–83
   PubMed Web of Science ®Google Scholar
• Mansfield P F, Hohn D C, Fornage B D, Gregurich M A, Ota D M. Complications and failures of subclavian-vein catheterization. N Engl J Med 1994; 331: 1735–9
   PubMed Web of Science ®Google Scholar
• Haire W D, Lieberman R P, Edney J, et al. Hickman catheter-induced thoracic vein thrombosis. Frequency and long-term sequelae in patients receiving high-dose chemotherapy and marrow transplantation. Cancer 1990; 66: 900–8
   PubMed Web of Science ®Google Scholar
• Eastridge B J, Lefor A T. Complications of indwelling venous access devices in cancer patients. J Clin Oncol 1995; 13: 233–8
   PubMed Web of Science ®Google Scholar
• Raad I I, Luna M, Khalil S AM, et al. The relationship between the thrombotic and infectious complications of central venous catheters. JAMA 1994; 271: 1014–6
   PubMed Web of Science ®Google Scholar
• Hjermstad M J, Kaasa S. Quality of life in adult cancer patients treated with bone marrow transplantation - a review of the literature. Eur J Cancer 1994; 31a: 163–73
   Google Scholar
• Andrykowski M A, Greiner C B, Altmaier E M, et al. Quality of life following bone marrow transplantation: findings from a multicentre study. Br J Cancer 1995; 71: 1322–9
   PubMed Web of Science ®Google Scholar
• Barton C, Waxman J. Effects of chemotherapy on fertility. Blood Rev 1990; 4: 187–95
   PubMedGoogle Scholar
• van Leeuwen F E, Stiggelbout A M, van den Belt, Dusebout A W, et al. Second cancer risk following testicular cancer: a follow-up study of 1909 patients. J Clin Oncol 1993; 11: 415–24
   PubMed Web of Science ®Google Scholar
• Doria R, Holford T, Farber L R, Prosnitz L R, Cooper D L. Second solid malignancies after combined modality therapy for Hodgkin's disease. J Clin Oncol 1995; 13: 2016–22
   PubMed Web of Science ®Google Scholar
• Rohatiner A. Myelodysplasia and acute myelogenous leukemia after myeloablative therapy with autologous stem-cell transplantation. J Clin Oncol 1994; 12: 2521–3
   PubMed Web of Science ®Google Scholar
• Tallman M S, Gray R, Bennet J M, et al. Leucogemic potential of adjuvant chemotherapy for early stage breast cancer: The Eastern Cooperative Oncology Group experience. J Clin Oncol 1995; 13: 1557–63
   PubMed Web of Science ®Google Scholar
• Crews J R, Vredenburgh J, Bigner S, et al. Incidence of myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) after high-dose chemotherapy (HOC) and autologous bone marrow transplant (ABMT). Proc Am Soc Clin Oncol 1995, Abstract 935
   Google Scholar
• Schuchter L M, Luginbuhl W E, Meropol N J. The current status of toxicity protectants in cancer therapy. Semin Oncol 1992; 19: 742–51
   PubMed Web of Science ®Google Scholar
• Glover D J, Glick J H, Weiler C, et al. WR-2721 protects against the hematologic toxicity of cyclophosphamide: a controlled phase II trial. J Clin Oncol 1986; 4: 584–8
   PubMed Web of Science ®Google Scholar
• Capizzi R L, Scheffler B J, Schein P S. Amifostinemediated protection of normal bone marrow from cytotoxic chemotherapy. Cancer 1993; 72: 2495–501
   PubMedGoogle Scholar
• Treskes M, Boven E, van de Loosdrecht A A, et al. Effects of the modulating agent WR-2721 on myelotoxicity and antitumour activity in carboplatin-treated mice. Eur J Cancer 1994; 30a: 183–7
   PubMed Web of Science ®Google Scholar
• Treskes M, Boven E, Holwerda U, et al. Time dependence of the selective modulation of cisplatin-induced nephrotoxicity by WR-2721 in the mouse. Cancer Res 1992; 52: 2257–60
   PubMed Web of Science ®Google Scholar
• Milas L, Hunter N R, Stephens L C, Petus L J. Inhibition of radiation carcinogenesis in mice by S-2-(3-aminopropylamino)-ethylphosphorothioic acid. Cancer Res 1984; 44: 5567–9
   PubMed Web of Science ®Google Scholar
• Shpall E J, Stemmer S M, Hami L, et al. Amifostine (WR-2721) shortens the engraftment period of 4-hydroperoxycyclophosphamide-purged bone marrow in breast cancer patients receiving high-dose chemotherapy with autologous bone marrow support. Blood 1994; 83: 3132–7
   PubMed Web of Science ®Google Scholar
• Patchen M L, MacVittie T J. Granulocyte colony-stimulating factor and amifostine (ethyol) synergize to enhance hemopoietic reconstitution and increase survival in irradiated animals. Semin Oncol 1994; 21: 26–32
   PubMed Web of Science ®Google Scholar
• Ayash L J, Wheeler C, Fairclough D, et al. Prognostic factors for prolonged progression-free survival with high-dose chemotherapy with autologous stem-cell support for advanced breast cancer. J Clin Oncol 1995; 13: 2043–9
   PubMed Web of Science ®Google Scholar
• Rahman Z, Frye D, Buzdar A, Hortobagyi G. A retrospective analysis to evaluate the selection process for high-dose chemotherapy (HDC) on the outcome of patients (PT) with metastatic breast cancer (MBC). Proc Am Soc Clin Oncol 1995, Abstract 78
   Google Scholar
• Bezwoda W R, Seymour L, Dansey R D. High-dose chemotherapy with hematopoietic rescue as primary treatment for metastatic breast cancer: a randomized trial. J Clin Oncol 1995; 13: 2483–9
   PubMed Web of Science ®Google Scholar
• Lazo J S. Endothelial injury caused by antineoplastic agents. Biochem Pharmacol 1986; 35: 1919–23
   PubMed Web of Science ®Google Scholar
• Smyth J, Bowman A, Perren T, et al. Glutathione improves the therapeutic index of cisplatin and quality of life for patients with ovarian cancer. Proc Am Soc Clin Oncol 1995, Abstract 761
   Google Scholar